Strong YTD cash from operations of $101 million compared to $88 million in the prior year; free operating cash flow of $57 million compared to $36 million in the prior year Earnings per diluted share (EPS) of $0.23 and adjusted EPS of $0.25 Returned approximately $31 million to shareholders; $15 million in share repurchases and $16 million in dividends Lowers fiscal 2025 full year outlook due to weakening market conditions, primarily in EMEAPITTSBURGH, Feb. 5, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KM ...

Core Insights - Kennametal Inc. has elected Douglas Dietrich to its Board of Directors, effective February 1, 2025, bringing over 30 years of industry experience [1][2] - Dietrich is currently the Executive Chairman and CEO of Minerals Technologies, where he has driven transformative change through strategic and operational leadership [2][3] - His expertise in strategy, innovation, and targeted M&A is expected to enhance Kennametal's growth and shareholder value [2][3] Company Overview - Kennametal has over 85 years of experience as an industrial technology leader, focusing on materials science, tooling, and wear-resistant solutions [7] - The company serves various sectors including aerospace, defense, energy, and transportation, employing approximately 8,400 people in nearly 100 countries [7] - Kennametal generated $2 billion in revenues in fiscal 2024 [7] Douglas Dietrich's Background - Dietrich has held key management positions at Minerals Technologies since joining in 2007, including Senior Vice President of Finance and Chief Financial Officer [4] - Prior to his role at Minerals Technologies, he held several leadership positions at Alcoa Inc., contributing to various sectors within the company [5] - Dietrich holds a Bachelor of Science in Mechanical Engineering from the University of Michigan and an MBA in Finance from The Wharton School at the University of Pennsylvania [6]

Company Overview - Kennametal Inc. has over 85 years of experience as an industrial technology leader, focusing on materials science, tooling, and wear-resistant solutions [2] - The company serves various sectors including aerospace and defense, earthworks, energy, general engineering, and transportation, helping customers manufacture with precision and efficiency [2] - Approximately 8,400 employees work across nearly 100 countries to support customer competitiveness [2] - Kennametal generated $2 billion in revenues in fiscal 2024 [2] Upcoming Events - Kennametal will attend the Barclays 42nd Annual Industrial Select Conference in Miami, Florida on February 19, 2025 [1] - Key attendees from the company include Patrick Watson, Vice President and Chief Financial Officer, and Michael Pici, Vice President of Investor Relations [1]

PITTSBURGH, Jan. 15, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) will host its second quarter fiscal year 2025 earnings call on Wednesday, February 5, 2025. The press release and presentation will be available on the Company's website before market on February 5.  Details of the conference call and webcast are as follows: When: Wednesday, February 5, 2025, at 9:30 am ET Hosts: Sanjay Chowbey, President and CEOPatrick Watson, Vice President and CFO Webcast:  The conference call ...

PITTSBURGH, Jan. 15, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that Faisal Hamadi, currently Vice President of Kennametal's Value Creation Systems, will succeed Franklin Cardenas as President of the Company's Infrastructure segment, effective January 20, 2025."I want to thank Franklin for his years of service and many contributions to Kennametal," said Sanjay Chowbey, President and CEO. "We wish him success in his future endeavors and appreciate his ongoing partnership with Faisal to ...

Kennametal Inc. (KMT) has been benefiting from strength in the Infrastructure segment, driven by solid momentum in the aerospace & defense and energy end markets arising from favorable order timing. The segment’s revenues inched up 0.4% year over year in the first quarter of fiscal 2025 (ended September 2024).The company is also witnessing several positive trends in its key end markets that hold promise for its long-term growth. This includes an increase in U.S. and international defense spending volumes an ...

Kennametal Inc. (KMT) is well-poised for growth in the coming quarters, courtesy of the strong performance of its Infrastructure segment. The company's efforts to reward its shareholders handsomely add to its appeal.Based in Latrobe, PA, Kennametal is a manufacturer, marketer and distributor of high-speed metal cutting tools, tooling systems and wear-resistant parts. Its products are marketed through a number of channels to the end users, comprising manufacturers of machine tools, transportation vehicles an ...

Kennametal Inc. (KMT) is benefiting from the strong performance of the Infrastructure segment, driven by strength in the aerospace & defense and energy end markets arising from favorable order timing. The segment’s revenues increased 0.4% year over year in the first quarter of fiscal 2025 (ended September 2024). Despite the ongoing softness across the majority of end markets, the company is witnessing several positive trends in its key end markets that hold promise for its long-term growth. This includes an ...

Core Insights - The FDA has approved Revuforj® (revumenib) as the first menin inhibitor for treating relapsed or refractory acute leukemia with a KMT2A translocation in patients aged one year and older [1][2][3] - The approval is based on positive data from the AUGMENT-101 clinical trial, demonstrating a 21% complete remission rate among treated patients [2][3] - Syndax Pharmaceuticals is preparing to launch Revuforj and is committed to advancing its development for KMT2A-rearranged acute leukemias and mutant NPM1 AML [2][8] Efficacy and Safety - In the AUGMENT-101 trial, 104 patients were evaluated, with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 21% [2] - The median duration of CR+CRh was 6.4 months, and the median time to CR or CRh was 1.9 months [2] - The safety evaluation involved 135 patients, with common adverse reactions including hemorrhage (53%), nausea (51%), and infection (41%) [3][18] Market Availability - Revuforj tablets (110 mg and 160 mg) are expected to be available for order in the U.S. in November 2024, with 25 mg tablets anticipated in early 2025 [4] - An oral solution of revumenib will be available through an expanded access program for patients weighing less than 40 kg prior to the commercial availability of the 25 mg tablets [4] Company Commitment - Syndax has established SyndAccess™, a program providing personalized support and financial assistance to U.S. patients prescribed Revuforj [5] - The company is focused on removing barriers to access for patients and enhancing support resources [5] Future Developments - Revumenib is also in development for treating R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1), with ongoing trials in combination with standard-of-care agents [8][9] - The company is conducting multiple clinical trials across the treatment landscape for KMT2A-rearranged acute leukemia and mNPM1 AML [8][22]

PITTSBURGH, Nov. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is proud to announce that it has been recognized as one of Caterpillar Inc's top indirect suppliers in 2024. This prestigious recognition reflects Kennametal's continued dedication to delivering innovative solutions, productivity improvements and outstanding customer and applications engineering support. Key drivers of this recognition include Kennametal's exceptional support in the successful launch of the Cat C27B and C32 cylinder head ...